TRIlogy-5 — JNJ-79635322 Versus Teclistamab in Relapsed or Refractory Multiple Myeloma
- EudraCT / EU CT No
- 2025-521372-62-00
- Protocol No
- 79635322MMY3002
Trial information
- Medical condition
- Relapsed or refractory multiple myeloma after 1–3 prior lines of therapy, including an anti-CD38 antibody and lenalidomide
- Trial phase
- Phase 3
- Sponsor
- Janssen Research & Development, LLC
- Start date
- 31/05/2026
- End date
- 08/12/2032
- Main objective
- Compare the efficacy and safety of JNJ-79635322 with teclistamab in participants with relapsed or refractory multiple myeloma.